Novel Mechanism of Action: JOTROL, their lead compound, targets neuroinflammation and mitochondrial dysfunction, offering a unique approach to neurological disorders beyond symptomatic treatment.

Broad Therapeutic Pipeline-in-a-Product Potential: JOTROL is being evaluated for multiple, diverse neurological indications, positioning it for significant market expansion if successful in one or more areas.

Addressing Significant Unmet Medical Needs: The company focuses on diseases like Alzheimer's, Parkinson's, and Friedreich's Ataxia, which currently have limited or no effective treatments, representing large patient populations and market opportunities.